MR generic application [Regulatives / Guidelines]

posted by vixen – Czechia, 2020-03-23 20:40 (1487 d 01:24 ago) – Posting: # 21296
Views: 2,125

Hi Mikkabel,
More details are needed to determine what we are dealing with here:
- presumably it's an application for Europe?
- is it a single or multiple unit formulation?
- what does the reference SmPC say about intake with/without food?
- is accumulation expected?
- do all three strengths meet the general biowaiver criteria per section 4.1.6 of the Guideline on the investigation of bioequivalence?
- is the shape of all three strengths similar?
- which two strengths represent the extremes? consider it separately for each of the factors listed by section 6.6. of EMA MR Guideline.

Are you familiar with Annex IV to the EMA Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms?

Cheers,
vixen

Complete thread:

UA Flag
Activity
 Admin contact
22,986 posts in 4,823 threads, 1,668 registered users;
41 visitors (0 registered, 41 guests [including 4 identified bots]).
Forum time: 23:04 CEST (Europe/Vienna)

Art is “I”; science is “we”.    Claude Bernard

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5